within Pharmacolibrary.Drugs.ATC.L;

model L03AB09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 4.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 9 / 1000000,
    adminCount     = 1,
    Vd             = 0.0108,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Interferon alfacon-1 is a synthetic, recombinant type I interferon with antiviral, antiproliferative, and immunomodulatory activities. It was primarily used for the treatment of chronic hepatitis C virus infection. It is not commonly used or approved today due to the introduction of more effective direct-acting antiviral agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults with chronic hepatitis C after subcutaneous administration.</p><h4>References</h4><ol><li><p>Melian, EB, &amp; Plosker, GL (2001). Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. <i>Drugs</i> 61(11) 1661–1691. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200161110-00009&quot;>10.2165/00003495-200161110-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11577799/&quot;>https://pubmed.ncbi.nlm.nih.gov/11577799</a></p></li><li><p>Cai, Y, et al., &amp; Liu, C (2012). Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs. <i>Regulatory peptides</i> 173(1-3) 74–81. DOI:<a href=&quot;https://doi.org/10.1016/j.regpep.2011.09.008&quot;>10.1016/j.regpep.2011.09.008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21985916/&quot;>https://pubmed.ncbi.nlm.nih.gov/21985916</a></p></li><li><p>Du, Y, et al., &amp; Yao, WB (2008). Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys. <i>Biopharmaceutics &amp; drug disposition</i> 29(8) 481–484. DOI:<a href=&quot;https://doi.org/10.1002/bdd.630&quot;>10.1002/bdd.630</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18985796/&quot;>https://pubmed.ncbi.nlm.nih.gov/18985796</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB09;
